Optimizing Early Intervention and Combination Strategies in Myelofibrosis

Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss the limitations of currently approved JAK inhibitors in the treatment of myelofibrosis.

Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss the importance of early intervention and when to initiate treatment in myelofibrosis.

Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss the mechanism of action of selinexor and the rationale for investigating the agent in myelofibrosis.

Prithviraj Bose, MD, and Pankit Vachhani, MD, overview the phase 3 SENTRY trial evaluating selinexor plus ruxolitinib in JAK inhibitor–naive myelofibrosis

Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss the key objectives of the phase 3 SENTRY trial evaluating selinexor plus ruxolitinib in JAK inhibitor–naive myelofibrosis.

Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss how selinexor plus ruxolitinib could affect the frontline myelofibrosis treatment paradigm.

Prithviraj Bose, MD, and Pankit Vachhani, MD, discuss how future